Our Business

Pipeline

Ad-SGE-REIC development pipeline

Ad-SGE-REIC development pipeline

* Prostate Cancer in Japan: We conducted clinical trials to develop more effective REIC formulation. Currently we have completed Phase II clinical trial.
* Malignant mesothelioma in US, Europe: IND (clinical trial) application to US Food and Drug Administration (FDA) was accepted on September 28, 2018.

As of March 31, 2018